Sponsor content
40 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial-single dose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial.
-
Australian public assessment report (AusPar)Spikevax XBB.1.5 (andusomeran) has been approved for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
-
Australian public assessment report (AusPar)Spikevax (Elasomeran/davesomeran), a vaccine, has transitioned from provisional to full registration. Spikevax is for the prevention of coronavirus disease 2019 caused by SARS-CoV-2.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX (elasomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial - multidose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX (elasomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
Australian public assessment report (AusPar)New AusPAR for Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2.
-
Designation or determinationPriority review